| 000 | 02478 a2200697 4500 | ||
|---|---|---|---|
| 005 | 20250514163058.0 | ||
| 264 | 0 | _c20040826 | |
| 008 | 200408s 0 0 eng d | ||
| 022 | _a0021-9150 | ||
| 024 | 7 |
_a10.1016/j.atherosclerosis.2003.07.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRaal, Frederick J | |
| 245 | 0 | 0 |
_aAvasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. _h[electronic resource] |
| 260 |
_bAtherosclerosis _cDec 2003 |
||
| 300 |
_a273-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAcetamides |
| 650 | 0 | 4 |
_aAcetates _xadministration & dosage |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAtorvastatin |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHeptanoic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aHyperlipoproteinemia Type II _xdiagnosis |
| 650 | 0 | 4 |
_aLipoproteins, HDL _xdrug effects |
| 650 | 0 | 4 |
_aLipoproteins, LDL _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 | _aProbability |
| 650 | 0 | 4 |
_aPyrroles _xadministration & dosage |
| 650 | 0 | 4 | _aReference Values |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 |
_aSterol O-Acyltransferase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSulfonamides |
| 650 | 0 | 4 |
_aSulfonic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aSterol O-Acyltransferase 2 |
| 700 | 1 | _aMarais, A David | |
| 700 | 1 | _aKlepack, Ellen | |
| 700 | 1 | _aLovalvo, Jennifer | |
| 700 | 1 | _aMcLain, Richard | |
| 700 | 1 | _aHeinonen, Therese | |
| 773 | 0 |
_tAtherosclerosis _gvol. 171 _gno. 2 _gp. 273-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.atherosclerosis.2003.07.011 _zAvailable from publisher's website |
| 999 |
_c14379110 _d14379110 |
||